Organon & Co. (NYSE:OGN) Declares Quarterly Dividend of $0.02

Organon & Co. (NYSE:OGN) announced a quarterly dividend on Monday, November 10th. Shareholders of record on Thursday, November 20th will be given a dividend of 0.02 per share on Thursday, December 11th. This represents a c) annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Thursday, November 20th.

Organon & Co. has a dividend payout ratio of 2.0% meaning its dividend is sufficiently covered by earnings. Analysts expect Organon & Co. to earn $3.74 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.1%.

Organon & Co. Trading Up 14.0%

OGN stock traded up $0.95 during mid-day trading on Monday, hitting $7.73. 16,794,529 shares of the company were exchanged, compared to its average volume of 7,567,873. Organon & Co. has a 12-month low of $6.18 and a 12-month high of $17.23. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. The business has a fifty day simple moving average of $9.37 and a 200-day simple moving average of $9.52. The firm has a market capitalization of $2.01 billion, a P/E ratio of 2.87, a PEG ratio of 0.61 and a beta of 0.59.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on OGN. Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. Piper Sandler lowered Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price objective for the company. in a report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $13.00.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.